Pulmatrix (PULM) Preferred Stock Liabilities (2013 - 2014)
Pulmatrix (PULM) posted Preferred Stock Liabilities of $1.3 million for Q4 2014, up 32625.0% sequentially from $4000.0 in Q4 2013, and up 32625.0% YoY from N/an in Q4 2013.
Pulmatrix (PULM) Preferred Stock Liabilities (2013 - 2014) Analysis & Trends
Pulmatrix has reported Preferred Stock Liabilities for 2 years, with the latest figure at $1.3 million in Q4 2014.
- Quarterly Preferred Stock Liabilities rose 32625.0% year-over-year to $1.3 million in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $1.3 million (up 32625.0% YoY) and the FY2014 annual result came in at $1.3 million, changed N/A from the prior year.
- Preferred Stock Liabilities improved to $1.3 million in Q4 2014 per PULM's latest filing, from $4000.0 in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $1.3 million in Q4 2014 and troughed at $4000.0 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pulmatrix | 5.46 Mn | 5.46 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 1.31 Mn |
| Dec 31, 2013 | 4,000.00 |